Yes, Botox and GLP-1 medications are safe to use together. There are no known drug interactions between neuromodulators(Botox, Dysport, Xeomin, Daxxify) and GLP-1 receptor agonists including semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). At Z Aesthetic Dermatology in Baton Rouge and Prairieville, many patients receive injectable treatments concurrently with their GLP-1 program.

The question comes up frequently because patients starting GLP-1 therapy are also seeing changes in their face — volume loss, shifting facial fat, and changes in skin quality — and want to know whether they can address those aesthetic changes while continuing their medication.

The short answer is yes. The longer answer is that your aesthetic plan may need to adapt as your body changes on GLP-1 therapy. Injectables placed when you had a fuller face may not look the same six months into a GLP-1 program. Dr. Z coordinates both at Z Aesthetic Dermatology — which is exactly why combining medical weight loss and injectables under one roof produces better outcomes.

• No interaction: neuromodulators and GLP-1 medications work on entirely different biological pathways — there is no contraindication
• Facial changes on GLP-1: patients commonly experience volume loss in the cheeks, temples, and under-eye area as weight decreases , timing of dermal filler adjustments matters
• Dr. Z's approach: coordinates your injectable plan with your weight loss progress, not a static plan that ignores body changes
• Botox timing: can be performed at any point during GLP-1 therapy — no required hold periods before or after injections
• Filler timing: for patients whose weight is still actively changing, Dr. Z may recommend waiting until weight stabilizes before significant filler volume additions

Related Reading:  Can You Get Botox on 

Semaglutide/Tirzepatide?

Z Aesthetic Dermatology is one of the only practices in Baton Rouge and Prairieville that manages both GLP-1 medical weight loss and full aesthetic injectable care under physician supervision — allowing Dr. Z to coordina

te changes to your injectable plan as your body transforms.

Weight loss injections in Baton Rouge at Z Aesthetic Dermatology are physician-prescribed GLP-1 receptor agonist medications, semaglutide and tirzepatide, delivered as once-weekly self-administered subcutaneous injections. They work by mimicking a naturally occurring gut hormone that signals fullness, slows gastric emptying, and reduces appetite at the brain level, producing sustained calorie redu

ction without requiring extreme willpower or restrictive dieting.

GLP-1 (glucagon-like peptide-1) is a hormone your body produces naturally after eating. GLP-1 receptor agonist medications amplify and extend that signal — dramatically reducing hunger, cravings, and food preoccupation for most patients. Clinical trials show average weight loss of 15–20% of body weight for well-adherent patients over 12–18 months.

At Z Aesthetic Dermatology in Baton Rouge, GLP-1 injections are prescribed and supervised by Dr. Ann Zedlitz, board-certified dermatologist — who also manages any aesthetic changes that occur during your weight loss journey.

• Semaglutide: active ingredient in Ozempic and Wegovy — weekly injection, 5+ years of clinical safety data
• Tirzepatide: active ingredient in Mounjaro and Zepbound — dual GIP/GLP-1 agonist, shown to produce greater average weight loss in clinical trials
• How they're administered: once-weekly self-injection with a small pen device, similar to an insulin pen
• What they do: reduce appetite, slow gastric emptying, regulate blood sugar — producing calorie deficit naturally
• What they don't do: burn fat directly — weight loss occurs through sustained reduction in caloric intake driven by dramatically reduced hunger

Weight loss injection consultations are available at Z Aesthetic Dermatology in Baton Rouge (Flanders Drive) and Prairieville (Old Jefferson Highway). Same-day consultation and prescription enrollment is available depending on scheduling.

Semaglutide (Wegovy/Ozempic) is a GLP-1 receptor agonist. Tirzepatide (Zepbound/Mounjaro) is a dual GIP and GLP-1 receptor agonist. Both produce significant weight loss, but tirzepatide activates an additional receptor pathway (GIP) that amplifies the weight loss effect — clinical trials show tirzepatide produces greater average weight loss than semaglutide: approximately 20–22% vs. 15% of body weight at maximum doses.

The practical difference is that tirzepatide's dual-mechanism action produces a more pronounced reduction in appetite for most patients — and the clinical trial data reflects this. The SURMOUNT-1 trial showed 22.5% average we

ight loss with tirzepatide at the highest dose, compared to approximately 15% with semaglutide in the STEP trials.

That said, individual response varies. Some patients respond exceptionally well to semaglutide. Both are appropriate first-line options. Dr. Z will recommend the right starting medication based on your medical history, prior medication use, and specific goals — not based on which drug is newest or more heavily marketed.

• Semaglutide (Ozempic/Wegovy): GLP-1 only, weekly injection, 5+ years of post-market safety data, widely studied
• Tirzepatide (Mounjaro/Zepbound): GIP + GLP-1 dual agonist, weekly injection, greater average weight loss in head-to-head comparisons
• Side effect profiles: similar — nausea, constipation, GI adjustment at dose escalation — though individual tolerance varies
• Cost: brand-name tirzepatide and semaglutide are similarly priced at high retail cost; covered by some insurance plans
• Which is right for you: determined at consultation with Dr. Z based on your complete medical profile

Both semaglutide and tirzepatide are available through the physician-supervised medical weight loss program at Z Aesthetic Dermatology in Baton Rouge and Prairieville, Louisiana.

Yes — physician-supervised GLP-1 medical weight loss with semaglutide and tirzepatide is available at Z Aesthetic Dermatology's Prairieville location on Old Jefferson Highway. Patients in Prairieville, Gonzales, Ascension Parish, and surrounding communities have access to the same physician-supervised program available at the Baton Rouge location, including full aesthetic coordination.

Z Aesthetic Dermatology's Prairieville practice serves patients throughout Ascension Parish who want physician-supervised GLP-1 care close to home — without driving to Baton Rouge. The Prairieville location offers the same full service menu: semaglutide, tirzepatide, injectable aesthetic treatments, Morpheus8, and skin care.

All GLP-1 programs at the Prairieville location are supervised by Dr. Ann Zedlitz, board-certified dermatologist — the same physician oversight available in Baton Rouge.

• Location: Z Aesthetic Dermatology Prairieville — Old Jefferson Highway, Prairieville, LA
• Services available: semaglutide, tirzepatide, GLP-1 consultations, dosing adjustments, aesthetic integration
• Serving: Prairieville, Gonzales, Sorrento, Geismar, Dutchtown, and surrounding Ascension Parish communities
• Physician supervised: all prescriptions issued and monitored by Dr. Ann Zedlitz, not a nurse practitioner or telehealth algorithm

Z Aesthetic Dermatology Prairieville is conveniently located for patients throughout Ascension Parish seeking physician-supervised GLP-1 weight loss care without traveling to Baton Rouge.

Yes — Z Aesthetic Dermatology in Baton Rouge prescribes semaglutide (the active ingredient in Ozempic and Wegovy) for physician-supervised medical weight loss. While Ozempic is the brand name for the diabetes formulation of semaglutide, Wegovy is the FDA-approved weight loss formulation at higher doses. Both use the same active molecule. Dr. Zedlitz, a board-certified physician, evaluates candidacy, prescribes, and supervises the full program.

Many patients search for 'Ozempic' because it's the most recognizable name associated with GLP-1 weight loss. At Z Aesthetic Dermatology, we prescribe semaglutide under the Wegovy formulation for weight loss — the FDA-approved dosing at the doses demonstrated to produce significant weight reduction in clinical trials.

We are not a telehealth service. Your prescription at Z Aesthetic Dermatology is issued after an in-person consultation with Dr. Z reviewing your complete medical history, current medications, and weight loss goals. Dosing is escalated under physician oversight — not auto-escalated based on a calendar.

• Ozempic vs. Wegovy: both contain semaglutide — Ozempic is FDA-approved for type 2 diabetes management; Wegovy is FDA-approved specifically for weight loss at higher doses
• What you get at Z Derm: physician consultation, candidacy assessment, prescription, dosing schedule, and ongoing monitoring — not a mail-order subscription
• Why it matters: GLP-1 medications have real contraindications and side effects that require physician oversight — not a self-reported intake form
• Insurance and cost: coverage varies; specific pricing discussed at consultation

Z Aesthetic Dermatology's Baton Rouge location on Flanders Drive offers physician-supervised semaglutide programs for qualifying patients in East Baton Rouge Parish and surrounding communities.

Rapid weight loss from GLP-1 therapy commonly causes facial volume loss — particularly in the cheeks, temples, and under-eye area — as well as increased skin laxity as fat that provided structural support is reduced. This is sometimes called 'Ozempic face.' At Z Aesthetic Dermatology in Baton Rouge, Dr. Z coordinates aesthetic treatment — including Botox, dermal fillers and Morpheus8 — with your GLP-1 program to address these changes as they occur.

The face is not immune to GLP-1-driven weight loss. Facial fat compartments that provide volume, structure, and a youthful appearance can diminish as total body fat decreases — sometimes resulting in a patient who looks thinner but older despite achieving their weight goal.

The advantage of managing weight loss at Z Aesthetic Dermatology is that your aesthetic provider and your weight loss physician are the same practice — allowing proactive planning for facial changes rather than reactive correction after they've occurred.

• What changes: cheek volume, temple fullness, under-eye hollowing, jowl laxity, and overall skin firmness can all be affected by GLP-1-driven weight loss
• Timing matters: Dr. Z typically advises against significant filler volume additions while weight is still actively changing — adjustments are better timed after stabilization
• What helps: strategic Botox and dermal fillers(Restylane, Radiesse) for volume restoration; Morpheus8 RF microneedling for skin tightening and collagen stimulation; Ultherapy for lifting
• Skin quality: VAMP PDRN microneedling supports overall skin regeneration during body transformation
• The Z Derm advantage: both services — GLP-1 and aesthetic correction — coordinated by Dr. Z under one roof

We are one of the few practices in Baton Rouge or Prairieville that offers coordinated GLP-1 medical weight loss and full-spectrum aesthetic management under a single board-certified physician — giving Z Aesthetic Dermatology patients a distinct advan

No — GLP-1 medications (semaglutide, tirzepatide) do not affect how Botox, Dysport, Xeomin, or Daxxify work. Neuromodulators block acetylcholine release at the neuromuscular junction. GLP-1 receptor agonists act on gut hormone receptors and the central nervous system to regulate appetite. These are entirely separate pathways with no interaction. There is no clinical evidence that GLP-1 medications alter the efficacy, onset, or duration of

 neuromodulator treatment.

This question comes up frequently because patients on GLP-1 therapy notice changes in how their face looks — softer tissue, less facial volume, shifting structure — and wonder whether the medication is affecting their Botox. The answer is that GLP-1 medications are changing the canvas, not the treatment. Botox works just as effectively, but the face it's working on may look different than it did before starting GLP-1 therapy.

This is why coordinating your aesthetic provider with your weight loss program matters. Dr. Z evaluates facial changes at each visit and adjusts injection technique and placement as your anatomy evolves — not simply repeating the same injection pattern from before you started GLP-1.

• No drug interaction: GLP-1 medications and neuromodulators operate on completely different receptor systems with no known interaction
• Botox efficacy: onset, duration, and effect are not altered by semaglutide or tirzepatide
• What does change: as facial volume shifts with weight loss, placement and dosing of neuromodulators may need adjustment — the treatment, not the drug interaction
• Ongoing monitoring: at Z Aesthetic Dermatology, Dr. Z reassesses your injection plan at each appointment, tracking facial changes during your GLP-1 program

Patients at Z Aesthetic Dermatology in Baton Rouge and Prairieville commonly manage both GLP-1 therapy and injectable treatments concurrently — the integrated care model means Dr. Z monitors both simultaneously.

'GLP-1 face' (also called 'Ozempic face') refers to the facial volume loss and increased skin laxity that can occur when patients lose significant weight rapidly on GLP-1 medications. A dermatologist treats GLP-1 face with a combination of Botox and dermal fillers to restore facial volume, Morpheus8 RF microneedling or Ultherapy to tighten lax skin, and coordinated injection timing to align with weight stabilization. At Z Aesthetic Dermatology in Baton Rouge, Dr. Z specializes in this integrated approach.

Related Reading:  Ozempic Face:  Why Weight Loss Can Change Your Facial Appearance and What You Can Do About It

The mechanism is straightforward: as body weight decreases on GLP-1 therapy, subcutaneous facial fat compartments that provide volume and structural support diminish proportionally. The skin surface area doesn't shrink as fast as the underlying fat does — resulting in hollowing, descent, and laxity that can make patients look older despite losing weight.

The dermatologist's advantage in treating GLP-1 face is understanding the facial anatomy and having the full treatment toolkit: fillers for volume, neurotoxins for muscle dynamics, energy devices for skin quality and tightening. A weight loss clinic without aesthetic expertise cannot coordinate this. A plastic surgeon typically begins at the surgical end of the spectrum. A board-certified dermatologist with aesthetic specialization — like Dr. Z — sits at the intersection.

• Volume restoration: Restylan
• e, Radiesse, Sculptra, or PRFM to restore cheek, temple, and under-eye volume lost during GLP-1 weight loss
• Skin tightening: Morpheus8 RF microneedling addresses skin laxity at the dermal level; Ultherapy PRIME addresses deeper lifting at the SMAS level
• Skin quality: VAMP PDRN microneedling and chemical peels support regeneration during body transformation
• Timing strategy: Dr. Z typically recommends waiting until weight stabilizes before adding significant filler volume — a treatment plan built for a face in transition must account for continued change
• Neuromodulator adjustment: as facial structure shifts, Botox/Dysport placement and dosing may need recalibration at each appointment

Z Aesthetic Dermatology in Baton Rouge and Prairieville is one of the only practices in the region that offers coordinated GLP-1 medical weight loss and physician-supervised aesthetic treatment — allowing patients to proactively manage GLP-1 face changes under one physician's care.

In Baton Rouge, you are typically a candidate for prescription GLP-1 weight loss medication if you have a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnea. Candidacy is determined at a physician consultation — not through a questionnaire. Dr. Ann Zedlitz reviews your complete medical history before prescribing.

FDA approval criteria for GLP-1 weight loss medications are based on body mass index (BMI) and the presence of weight-related comorbidities. However, FDA criteria are a floor, not a complete candidacy determination. Contraindications — including a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, or pregnancy — must be ruled out before prescribing. This requires a real medical history review, not a checkbox intake form.

At Z Aesthetic Dermatology, Dr. Z conducts a complete in-person consultation before any GLP-1 prescription. This is standard physician practice — and it's how we identify patients who would genuinely benefit, and patients for whom a different approach makes more sense.

• BMI ≥ 30: qualifies for GLP-1 without additional conditions required
• BMI 27–29.9 with comorbidity: qualifies with at least one weight-related condition — hypertension, T2 diabetes, high cholesterol, OSA
• Absolute contraindications: personal or family history of medullary thyroid cancer, MEN2 syndrome, active pancreatitis, pregnancy
• What the consultation includes: complete medical history review, current medication assessment, BMI evaluation, goal-setting, and medication recommendation
• Telehealth vs. in-person: telehealth services often skip the in-person history review — Z Aesthetic Dermatology requires it

Physician-supervised GLP-1 candidacy consultations are available at Z Aesthetic Dermatology in Baton Rouge and Prairieville. Same-week consultations are frequently available — contact us to check availability.